BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.
Jennings, L.E., Schiedel, M., Hewings, D.S., Picaud, S., Laurin, C.M.C., Bruno, P.A., Bluck, J.P., Scorah, A.R., See, L., Reynolds, J.K., Moroglu, M., Mistry, I.N., Hicks, A., Guzanov, P., Clayton, J., Evans, C.N.G., Stazi, G., Biggin, P.C., Mapp, A.K., Hammond, E.M., Humphreys, P.G., Filippakopoulos, P., Conway, S.J.(2018) Bioorg Med Chem 26: 2937-2957
- PubMed: 29776834 
- DOI: 10.1016/j.bmc.2018.05.003
- Primary Citation of Related Structures:  
6FSY, 6FT3, 6FT4 - PubMed Abstract: 
Ligands for the bromodomain and extra-terminal domain (BET) family of bromodomains have shown promise as useful therapeutic agents for treating a range of cancers and inflammation. Here we report that our previously developed 3,5-dimethylisoxazole-based BET bromodomain ligand (OXFBD02) inhibits interactions of BRD4(1) with the RelA subunit of NF-κB, in addition to histone H4 ...